Skip to content

G Caleb Alexander

2 papers in the library · publishing 2022-2026

Papers

Sort Most recent Most cited

Esketamine Use and Attempted Suicide or Intentional Self-Harm Among Individuals with Treatment-Resistant Depression: A Retrospective Cohort Study.

Drug safety September 2, 2026 You Wang, Alexandra S Storaci, G Caleb Alexander et al.

Treatment-resistant depression (TRD) is associated with elevated suicide risk, but real-world evidence on whether esketamine reduces suicide attempts and intentional self-harm remains limited. The aim was to estimate whether current esketamine exposure was associated with a higher or lower risk of recorded nonfatal, medically attended suicide attempt or intentional self-harm among adults with...

Safety and effectiveness of NMDA receptor antagonists for depression: A multidisciplinary review.

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy July 2022 Thomas J Moore, Abdallah Alami, G Caleb Alexander et al.

Ketamine, an anesthetic available since 1970, and esketamine, its newer S-enantiomer, provide a novel approach for the treatment of depression and other psychiatric disorders. At subanesthetic doses, the two drugs, along with their older congener, phencyclidine (PCP), induce a transient, altered mental state by blocking the N-methyl-D-aspartate (NMDA) receptor for glutamate, the primary...

DOI: 10.1002/phar.2707 (opens in new tab) Full text (opens in new tab) Esketamine Drug approval Evidence-based toxicology Ketamine hydrochloride +1